Screener
Abbott ABT Established Pharmaceuticals — Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Abbott in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Abbott’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:02 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050134
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Int’l | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Int’l | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|
| Established Pharmaceutical Products — | ||||||
| Key Emerging Markets | — | $1,164 | $1,164 | — | $1,059 | $1,059 |
| Other | — | 335 | 335 | — | 324 | 324 |
| Total | — | 1,499 | 1,499 | — | 1,383 | 1,383 |
| Nutritional Products — | ||||||
| Pediatric Nutritionals | 525 | 500 | 1,025 | 587 | 467 | 1,054 |
| Adult Nutritionals | 346 | 773 | 1,119 | 370 | 788 | 1,158 |
| Total | 871 | 1,273 | 2,144 | 957 | 1,255 | 2,212 |
Item 1. Financial Statements and Supplementary Data
FAQ
- What is Abbott's established pharmaceuticals — net sales?
- Abbott (ABT) reported established pharmaceuticals — net sales of $1.5B in Q2 2026.
- How has Abbott's established pharmaceuticals — net sales changed year-over-year?
- Abbott's established pharmaceuticals — net sales increased by 8.4% year-over-year, from $1.38B to $1.5B.
- What is the long-term trend for Abbott's established pharmaceuticals — net sales?
- Over 4 years (2021 to 2025), Abbott's established pharmaceuticals — net sales has grown at a 4.1% compound annual growth rate (CAGR), from $4.72B to $5.54B.
- What does established pharmaceuticals — net sales mean?
- This metric represents the total revenue generated from the sale of branded generic pharmaceutical products within the established pharmaceuticals segment. It reflects the market demand and pricing power of the company's mature drug portfolio across various international markets. Growth in this metric indicates successful commercial execution and market penetration in emerging and developed regions.
Ask your AI about Abbott's established pharmaceuticals — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude